235 related articles for article (PubMed ID: 37088816)
21. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Garvin Mayo W; Gai X; Carey J; Carson R; Moreau P
J Clin Oncol; 2023 Mar; 41(8):1590-1599. PubMed ID: 36599114
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
LeBlanc R; Mian H; Reece D; Masih-Khan E; Kardjadj M; Jimenez-Zepeda VH; McCurdy A; Song K; Sebag M; Louzada M; White D; Stakiw J; Kotb R; Reiman A; Aslam M; Gul E; Venner CP
Br J Haematol; 2022 Jul; 198(1):93-102. PubMed ID: 35383886
[TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
25. Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome.
Beksac M; Seval GC; Koyun D; Topcuoglu P; Yuksel MK; Gurman G; Ilhan O
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e164-e170. PubMed ID: 36610852
[TBL] [Abstract][Full Text] [Related]
26. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Zagouri F; Roussou M; Kastritis E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kalapanida D; Christoulas D; Migkou M; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2016 Aug; 57(8):1776-80. PubMed ID: 26916452
[TBL] [Abstract][Full Text] [Related]
28. Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Sandecka V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Pavlíček P; Jungová A; Kessler P; Wróbel M; Štork M; Štraub J; Pika T; Čápková L; Ševčíková S; Maisnar V; Hájek R
Neoplasma; 2022 Dec; 69(6):1474-1479. PubMed ID: 36591805
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study.
Sunami K; Murakami H; Tagashira H; Ueda H; Moriyama T; Ishikawa T; Yoshioka T; Makita M
Int J Clin Oncol; 2020 Dec; 25(12):2151-2157. PubMed ID: 32715356
[TBL] [Abstract][Full Text] [Related]
30. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
[TBL] [Abstract][Full Text] [Related]
31. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
32. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
[TBL] [Abstract][Full Text] [Related]
33. Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma.
Zhou X; Ruckdeschel A; Peter J; Böckle D; Hornburger H; Danhof S; Steinhardt MJ; Heimeshoff L; Einsele H; Kortüm KM; Rasche L
Hematol Oncol; 2022 Apr; 40(2):202-211. PubMed ID: 34796520
[TBL] [Abstract][Full Text] [Related]
34. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.
Derman BA; Zonder J; Reece D; Cole C; Berdeja J; Stefka AT; Major A; Kin A; Griffith K; Jasielec J; Jakubowiak AJ
Blood Adv; 2023 Oct; 7(19):5703-5712. PubMed ID: 36763537
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
Suzuki K; Dimopoulos MA; Takezako N; Okamoto S; Shinagawa A; Matsumoto M; Kosugi H; Yoon SS; Huang SY; Qin X; Qi M; Iida S
Blood Cancer J; 2018 May; 8(4):41. PubMed ID: 29712896
[TBL] [Abstract][Full Text] [Related]
38. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A; Derudas D; Galli M; Martino EA; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Farina G; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Pietrantuono G; Palumbo G; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; Mendicino F; Iaccino E; Mimmi S; Botta C; Vincelli D; Sgherza N; Bonalumi A; Cupelli L; Stocchi R; Martino M; Ballanti S; Gangemi D; Gagliardi A; Gamberi B; Pompa A; Tripepi G; Frigeri F; Consoli U; Bringhen S; Zamagni E; Patriarca F; De Stefano V; Di Raimondo F; Palmieri S; Petrucci MT; Offidani M; Musto P; Boccadoro M; Cavo M; Neri A; Morabito F; Gentile M
Hematol Oncol; 2022 Oct; 40(4):704-715. PubMed ID: 35608183
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Maisnar V; Stefanikova Z; Spicka I; Pour L; Minarik J; Flochova E; Radocha J; Gregora E; Stecova N; Jelinek T; Jungova A; Kralikova E; Brozova L; Hajek R
Neoplasma; 2019 May; 66(3):499-505. PubMed ID: 30784289
[TBL] [Abstract][Full Text] [Related]
40. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Liu J; He HY; Li L; Lu J; Qiang WT; Guo P; Hou N; Jiang H; Du J; Fu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):27-32. PubMed ID: 33677865
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]